XML 22 R11.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition
3 Months Ended
Mar. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Revenue Recognition
During the three months ended March 31, 2019, the Company recognized total revenue under collaborative research and development and other agreements of $2.7 million from AstraZeneca and $117,000 from various other contracts. The Company defers revenue when a contract is entered into with a collaborator and cash payments are received prior to satisfaction of the related performance obligation. Of the total revenue recognized during the three months ended March 31, 2019, $179,000 was in deferred revenue as of December 31, 2018. During the three months ended March 31, 2018, the Company recognized revenue of $652,000 that was included in deferred revenue at December 31, 2017. Performance obligations are generally satisfied within 12 months of the initial contract date.